Jimmy Kimmel's Oscars monologue turns Ozempic into a punchline

Two minutes into hosting the 95th Academy Awards on Sunday, March 12, Jimmy Kimmel looked out at the audience and said: "Everybody looks so great. When I look around this room, I can't help but wonder 'Is Ozempic right for me?'" ^[1][2] The line drew laughter in the room and an immediate wave of social media commentary, and it is now widely treated as the point where a prescription diabetes medicine crossed fully into American pop culture ^[1].

The joke's structure borrowed the cadence of a drug commercial, and the reaction online suggested viewers had been expecting it. "BINGO CARD! Took less than two minutes for Jimmy Kimmel to make an Ozempic quip!" one viewer posted ^[1]. Another wrote, "Can't believe Jimmy Kimmel made an open reference to Ozempic in front of all of Hollywood" ^[1].

What the drug actually is

Ozempic is the brand name for semaglutide, one of several medicines in a class known as incretins ^[2]. It is given as a weekly injection ^[2]. In June 2021, the Food and Drug Administration approved semaglutide under a different brand name, Wegovy, as a treatment for chronic obesity, and interest in the drug has climbed sharply since ^[2]. Coverage of the Oscars joke repeatedly described Ozempic itself as a diabetes drug being used off its intended purpose for weight loss ^[1][2].

Few celebrities have confirmed using it. Elon Musk and Chelsea Handler are among the small number of well-known names who have acknowledged using the drug for weight loss, and Handler said she stopped after learning it was intended for people with diabetes ^[2]. Experts quoted by USA TODAY said most celebrities who use it are likely staying quiet ^[2].

The side effects and the supply problem

Alongside the cultural attention, plastic surgeons and dermatologists have warned about "Ozempic face" — premature facial aging that can follow the weight loss ^[1]. Separately, USA TODAY reported that the growing number of people using Ozempic, famous or not, has created a shortage for people with diabetes who rely on it for their health ^[2].

Researchers interviewed about the trend framed it as a body-image story as much as a medical one. Meghan Gillen, an associate professor of psychology at Penn State Abington who studies body image, said the idea of an "ideal" body type can trigger "feelings of shame and lack of self-worth, anxiety and depression" ^[2]. Sports Illustrated model Ella Halikas said the trend is "really, really damaging and making us all spiral back into skinny culture," adding that if it had happened when she was in high school, "I would be begging my mom to take me to get the shots" ^[2].

Why it matters for patients

For people already taking semaglutide, or considering it, the Oscars moment matters in three practical ways.

First, supply. Demand driven by weight-loss interest was tied directly to a shortage affecting people with diabetes who take Ozempic as prescribed ^[2]. That is a pharmacy-counter problem, not a red-carpet one.

Second, the gap between brands. Ozempic and Wegovy are both semaglutide, but only Wegovy carries the FDA approval for chronic obesity granted in June 2021 ^[2]. Jokes and headlines tend to collapse the two into one name, which can blur what a given prescription is actually approved to treat.

Third, expectations. The public conversation is running on celebrity before-and-after images rather than on documented results or side effects. Gillen noted that research suggests explaining how a celebrity lost weight would not necessarily make most people feel better about themselves; one study found that adding disclaimers to Photoshopped body images did not stop viewers from comparing themselves to the edited pictures ^[2]. Cosmetic effects like the facial changes clinicians have described are part of the picture too ^[1].

What happens next

The sources do not give a timeline for when the Ozempic shortage affecting people with diabetes would ease, and they do not report any response from the manufacturer to the Oscars joke ^[1][2]. Whether the cultural attention translates into more prescriptions, more scrutiny, or both is not established in this reporting.